Lv6
1850 积分 2021-04-08 加入
Trastuzumab deruxtecan in HER2-low metastatic breast cancer: long-term survival analysis of the randomized, phase 3 DESTINY-Breast04 trial
1个月前
已完结
HER2 testing: evolution and update for a companion diagnostic assay
1个月前
已完结
Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial
1个月前
已完结
Neoadjuvant atezolizumab and chemotherapy in patients with resectable non-small-cell lung cancer: an open-label, multicentre, single-arm, phase 2 trial
2个月前
已完结
[Guidelines on tests of PIK3CA mutation in breast cancer in China (2025 version)]
3个月前
已完结
Evolving trends in surgically managed lung Cancer: A 16-Year Hospital-Based epidemiological analysis
3个月前
已完结
Survival with Trastuzumab Emtansine in Residual HER2-Positive Breast Cancer
3个月前
已完结
Neratinib after trastuzumab-based adjuvant therapy in patients with HER2-positive breast cancer (ExteNET): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial
3个月前
已完结
The Latest Research and Development into the Antibody–Drug Conjugate, [fam-] Trastuzumab Deruxtecan (DS-8201a), for HER2 Cancer Therapy
3个月前
已完结
1318P Four-year outcomes from GEMSTONE-302 study: First-line sugemalimab plus platinum-based chemotherapy in metastatic non-small cell lung cancer (NSCLC)
3个月前
已完结
皖公网安备34019202002308
